Structure/class |
- A carboxylic acid
|
Pharmacodynamics |
- Works by blocking Na+ current and therefore, probably blocking sustained high frequency repetitive firing of neurons.
- May reduce NMDA receptor excitation
- May also increase GABA levels.
All the above act to stabilize membrane potential and reduce seizure activity. |
Administration |
- PO, IV
|
Distribution |
- Bioavailability of 80%
- It is very highly bound to plasma protein and very ionized – the Vd is essentially confined to extracellular water (0.15L/kg). This makes it a dialyzable toxin.
|
Metabolism |
- Hepatic enzymes.
- T ½ ~15 hours.
|
Excretion |
- Urine
|
Indications |
- GTCS
- Absence seizures (the drug of choice)
- Useful in controlling myoclonic seizures
- Can be used IV to treat status epilepticus
- Bipolar disorder
- Migraine prophylaxis
|
Contraindications |
|
Special precautions |
|
Interactions |
- Na Valproate is an enzyme inhibitor – in increases the level of phenytoin and carbamazepine, as well as phenobarbital.
- Because it is highly bound to plasma proteins, it displaces phenytoin from its binding site.
|
Adverse events |
- Neurological SES – ataxia, fine tremor, coma and cerebral oedema in major OD.
|
Dosing/administration |
|
Toxicology |
- Idiosyncratic reaction – severe hepatotoxicity (especially in the very young patients, or if patient already has pre-existing liver disease, and also if there are other hepatotoxins).
- N/V, GIT upset
- Thrombocytopaenia
- Birth defects – spina bifida/CVS, orofacial abnormality
|
Withdrawal syndrome |
|
Special notes |
|